TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00003954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous bone marrow or PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Undergo autologous bone marrow or PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous bone marrow or PBSCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo donor PBSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Undergo DLI
Study: NCT04802538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OstoRing®
Description: Participants will use the OstoRing® along with their standard pouching equipment.
Study: NCT04351867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel plus oxaliplatin and capecitabine
Description: docetaxel 50mg/㎡ ivgtt. d1+oxaliplatin 100mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin plus capecitabine
Description: oxaliplatin 130mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
Study: NCT04214704

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genteel lancing device
Description: Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genteel lancing device
Description: Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional lancing device
Description: Conventional lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional lancing device
Description: Conventional lancing device
Study: NCT04513990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of nasopharyngeal, oral, saliva, and nasal samples
Study: NCT02916381

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: General anaesthesia
Study: NCT04513990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Demographic information, sample collection type preferences; clinical outcome information
Study: NCT03213158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Oral Capsule
Description: Highly sensitized kidney transplant candidates on the waitlist for more than 24 months will receive ixazomib 3 mg (and dexamethasone 20 mg) on days 1, 8, and 15 of a 28 cycle. Patients will take ixazomib and dexamethasone for twelve (12) 28-day cycles.
Study: NCT01117064

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromodulation Therapy Device (NMTD)
Description: Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized). we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromodulation Therapy Device (NMTD)
Description: Subjects will have an overnight PSG using the NMTD. This device detects reduced airflow via a polymer sensor. When such event is detected, a short burst of sound is administered via earphones. We will determine NMTD's operating characteristics for treatment of OSA. The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined. Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone. Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromodulation Therapy Device (NMTD)
Description: Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
Study: NCT03977038

Intervention type: DEVICE
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is prescribed as first-line treatment for TRD patients (4). rTMS is safe, tolerable and non-invasive neurostimulation procedure where powerful magnetic pulses are transmitted through the skull into the underlying cortical cortex with the aim of electrical current induction within the neural tissue. This study administers a standard dose of rTMS treatment to the TRD patient sample consisting of high frequency deep TMS (HF-dTMS) stimulation over left dorsolateral prefrontal cortex (L-DLPFC), at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks. The technology of dTMS, which will be used in this study, is an adaptation of the therapeutic intervention of rTMS with the advancement of possessing higher efficacy in targeting deeper brain regions of interest.
Study: NCT01684748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Description: Crossover intervention comparing antihypertensive medication to no drug intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Description: Crossover intervention comparing antihypertensive medication to no drug intervention.
Study: NCT03185533

Intervention type: BEHAVIORAL
Intervention: Quality improvement (QI) interventions
Description: 1. The ED admissions exhibited prolonged length of stay.~2. The Interventions for Reducing Medical Decision Time:~1. The ED director created QI education sessions and reported monthly QI outcomes.~2. The ED nurses reported the current number of ED admission patients twice a day to the director. The director summarized the bed requests to the administrative personnel.~3. The nurses reported the in-scene complicated cases to the ED director. The director would give an assistance in managing these cases.~3. The Interventions for Reducing Boarding Time~1. The ED patients could be admitted before 8 a.m. if the bed was vacant.~2. The ED director initiated an on-line meeting at 8 a.m. and 4 p.m.~3. Monthly QI outcomes were reported in the hospital affairs meeting.
Study: NCT00970138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib tablet
Description: A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib tablet
Description: A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: apatinib tablet
Description: A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT04329039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin analog
Description: Somatostatin analog plus perioperative antibiotics Placebo plus perioperative antibiotics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Somatostatin analog
Description: Somatostatin analog plus perioperative antibiotics Placebo plus perioperative antibiotics
Study: NCT03943030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
Study: NCT04568434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Olezarsen will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olezarsen-matching placebo will be administered by SC injection.
Study: NCT03231085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate or ferrostrane
Description: Young children operated with craniosynostosis and treated with EPO and ferrous fumarate or ferostrane per os or intravenous ferric carboxymaltose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate or ferrostrane
Description: Young children operated with craniosynostosis and treated with EPO and ferrous fumarate or ferostrane per os or intravenous ferric carboxymaltose.
Study: NCT00884585

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine Vehicle
Description: Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.010%
Description: Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine 0.010%
Description: Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
Study: NCT03756051

Intervention type: OTHER
Intervention: Prospective Longitudinal Data
Description: We will prospectively follow the cohort using electronic medical record to document the hepatocellular carcinoma screening process and characterize physical and financial harms related to positive or indeterminate screening results and burden of inappropriate screening. Patients are anticipated to undergo hepatocellular carcinoma screening every 6-12 months, so each patient will have \~4-8 screening encounters over the study duration. We will use manual chart review to determine intent of ultrasound exams (screening vs. diagnostic) and test results. Receipt of follow-up tests after positive or indeterminate screening results will be identified through electronic medical record extraction using Current Procedural Terminology (CPT) codes for CT, MRI, and biopsy.

Intervention type: OTHER
Intervention: Surveys and Semi-structured Interviews
Description: We will use surveys and semi-structured interviews to characterize psychological harms after positive or indeterminate screening tests. Patient surveys will include patient-reported scales to measure psychosocial factors at three times points: baseline, 1 month after screening result, and 4 months after screening result. Semi-structured interviews will be conducted via telephone to explore patient attitudes toward risk perception, test follow-up, competing demands, and downstream harms, particularly financial issues (e.g., out-of-pocket costs, access to insurance, and juggling hepatocellular carcinoma screening process completion with competing demands-work and family).
Study: NCT03746366

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]
Description: Radiolabel
Study: NCT03777436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Oral
Study: NCT03746366

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]
Description: Radiolabel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pittsburgh Compound B
Description: Tracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pittsburgh Compound B
Description: Tracer
Study: NCT05729763

Intervention type: OTHER
Intervention: 3D-PADUA nephrometric score
Description: Evaluation of the PADUA nephrometric score with 3D images

Intervention type: OTHER
Intervention: 2D-PADUA nephrometric score
Description: Evaluation of the PADUA nephrometric score with 2D images
Study: NCT00827918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8998
Description: MK-8998 6 mg capsules twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 8 mg capsules twice daily. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Olanzapine
Description: Olanzapine 5 mg tablets twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 5 mg tablets in the morning and 10 mg tablets in the evening. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablets matching olanzapine tablets and MK-8998 capsules
Study: NCT01632748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurotech Vital Device
Description: 5 minute treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Neurotech Vital Device
Description: 5 minute stimulation
Study: NCT04231812

Intervention type: DEVICE
Group type: OTHER
Intervention: Laparoscopic Tissue Morcellation working space (bag)
Description: The LapBox is working space (bag) intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy
Study: NCT02806375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: Day 0: Infusion of unmanipulated graft

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Days -5 through -3: Busulfan 1 mg/kg po qid №10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate
Description: Days -7 through -2: 30 mg/m2/day iv qd x 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day +3 and +4: 50 mg/kg/day iv qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Days -8 through -2 15 mg tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Days +5 through +100: 7.5 mg bid
Study: NCT03479320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Postoperative analgesic effects will be compared between lidocaine and normal saline group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Postoperative anlagesic requirements will be calculated and compared with experimental group
Study: NCT04240366

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control intervention
Description: patients treated with balloon-based ablation of AF by PVI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Description: patients treated with balloon-based ablation of AF by PVI
Study: NCT01302847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG film-coated tablets
Description: DTG film-coated tablets initial starting dose at \~1 mg/kg with a maximum dose of 50 mg; orally once daily. Participants weighing ≥ 35kg received the proposed dose of 50 mg of DTG film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG film-coated tablets
Description: DTG film-coated tablets initial starting dose at \~1 mg/kg with a maximum dose of 50 mg; orally once daily. Participants weighing ≥ 35kg received the proposed dose of 50 mg of DTG film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG granules for suspension
Description: DTG granules for suspension initial starting dose at \~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG granules for suspension
Description: DTG granules for suspension initial starting dose at \~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG granules for suspension
Description: DTG granules for suspension initial starting dose at \~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG dispersible tablets
Description: DTG dispersible tablets initial starting dose of \~0.8 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG dispersible tablets
Description: DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG dispersible tablets
Description: DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets.
Study: NCT04630431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo standard of care follow-up

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Undergo standard of care follow-up

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Undergo clinical trial education via a video and educational booklet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo clinical trial education via a video and educational booklet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Review of medical record

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Review of medical record

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Review of medical record

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Undergo clinical trial navigation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT02180061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT03623256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal fentanyl
Description: 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal bupivacaine
Description: 1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Fentanyl and Bupivacaine
Description: 1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL), and 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl /spinal bupivacaine
Description: 1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route, and 100 mcg of fentanyl (2 mL) will be administered by epidural route.
Study: NCT02539563

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peanut shaped birthing ball
Description: peanut ball will be utilized
Study: NCT01429402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 1-2U/kg, at 25U/mL, into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site; only once after surgery. No additional injection is needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Type A
Description: b. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room just after surgery. (total dosage injected 15U)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).